Daamen Marcel, Scheef Lukas, Li Shumei, Grothe Michel J, Gaertner Florian C, Buchert Ralph, Buerger Katharina, Dobisch Laura, Drzezga Alexander, Essler Markus, Ewers Michael, Fliessbach Klaus, Herrera Melendez Ana Lucia, Hetzer Stefan, Janowitz Daniel, Kilimann Ingo, Krause Bernd Joachim, Lange Catharina, Laske Christoph, Munk Matthias H, Peters Oliver, Priller Josef, Ramirez Alfredo, Reimold Matthias, Rominger Axel, Rostamzadeh Ayda, Roeske Sandra, Roy Nina, Scheffler Klaus, Schneider Anja, Spottke Annika, Spruth Eike Jakob, Teipel Stefan J, Wagner Michael, Düzel Emrah, Jessen Frank, Boecker Henning
German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
Department for Diagnostic and Interventional Radiology, University Hospital Bonn, Bonn, Germany.
J Alzheimers Dis. 2023;95(3):1013-1028. doi: 10.3233/JAD-230141.
Atrophy of cholinergic basal forebrain (BF) nuclei is a frequent finding in magnetic resonance imaging (MRI) volumetry studies that examined patients with prodromal or clinical Alzheimer's disease (AD), but less clear for individuals in earlier stages of the clinical AD continuum.
To examine BF volume reductions in subjective cognitive decline (SCD) participants with AD pathologic changes.
The present study compared MRI-based BF volume measurements in age- and sex-matched samples of N = 24 amyloid-positive and N = 24 amyloid-negative SCD individuals, based on binary visual ratings of Florbetaben positron emission tomography (PET) measurements. Additionally, we assessed associations of BF volume with cortical amyloid burden, based on semiquantitative Centiloid (CL) analyses.
Group differences approached significance for BF total volume (p = 0.061) and the Ch4 subregion (p = 0.059) only, showing the expected relative volume reductions for the amyloid-positive subgroup. There were also significant inverse correlations between BF volumes and CL values, which again were most robust for BF total volume and the Ch4 subregion.
The results are consistent with the hypothesis that amyloid-positive SCD individuals, which are considered to represent a transitional stage on the clinical AD continuum, already show incipient alterations of BF integrity. The negative association with a continuous measure of cortical amyloid burden also suggests that this may reflect an incremental process. Yet, further research is needed to evaluate whether BF changes already emerge at "grey zone" levels of amyloid accumulation, before amyloidosis is reliably detected by PET visual readings.
胆碱能基底前脑(BF)核萎缩在针对前驱期或临床阿尔茨海默病(AD)患者的磁共振成像(MRI)容积测量研究中是常见发现,但对于临床AD连续体早期阶段的个体情况尚不清楚。
研究有AD病理改变的主观认知下降(SCD)参与者的BF体积减少情况。
本研究基于氟代贝他班正电子发射断层扫描(PET)测量的二元视觉评级,比较了年龄和性别匹配的N = 24例淀粉样蛋白阳性和N = 24例淀粉样蛋白阴性SCD个体样本中基于MRI的BF体积测量结果。此外,我们基于半定量的百慕大(CL)分析评估了BF体积与皮质淀粉样蛋白负荷的相关性。
仅BF总体积(p = 0.061)和Ch4亚区域(p = 0.059)的组间差异接近显著,显示淀粉样蛋白阳性亚组出现预期的相对体积减少。BF体积与CL值之间也存在显著的负相关,同样在BF总体积和Ch4亚区域最为显著。
结果与以下假设一致,即被认为代表临床AD连续体过渡阶段的淀粉样蛋白阳性SCD个体已经显示出BF完整性的早期改变。与皮质淀粉样蛋白负荷连续测量值的负相关也表明这可能反映了一个渐进过程。然而,需要进一步研究以评估在PET视觉读数可靠检测到淀粉样变性之前,BF变化是否已经在淀粉样蛋白积累的“灰色区域”水平出现。